| Literature DB >> 26863487 |
Steve Stegen1, Nick van Gastel1, Guy Eelen2, Bart Ghesquière2, Flora D'Anna3, Bernard Thienpont3, Jermaine Goveia2, Sophie Torrekens4, Riet Van Looveren4, Frank P Luyten5, Patrick H Maxwell6, Ben Wielockx7, Diether Lambrechts3, Sarah-Maria Fendt8, Peter Carmeliet2, Geert Carmeliet9.
Abstract
Cell-based therapy is a promising strategy in regenerative medicine, but the poor survival rate of the implanted cells remains a major challenge and limits clinical translation. We preconditioned periosteal cells to the hypoxic and ischemic environment of the bone defect site by deleting prolyl hydroxylase domain-containing protein 2 (PHD2), resulting in hypoxia-inducible factor 1 alpha (HIF-1α) stabilization. This strategy increased postimplantation cell survival and improved bone regeneration. The enhanced cell viability was angiogenesis independent but relied on combined changes in glutamine and glycogen metabolism. HIF-1α stabilization stimulated glutaminase-mediated glutathione synthesis, maintaining redox homeostasis at baseline and during oxidative or nutrient stress. Simultaneously, HIF-1α signaling increased glycogen storage, preventing an energy deficit during nutrient or oxygen deprivation. Pharmacological inhibition of PHD2 recapitulated the adaptations in glutamine and glycogen metabolism and, consequently, the beneficial effects on cell survival. Thus, targeting cellular metabolism is an appealing strategy for bone regeneration and cell-based therapy in general.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26863487 PMCID: PMC7611069 DOI: 10.1016/j.cmet.2016.01.002
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287